Silo Pharma Inc., a developmental stage biopharmaceutical company, has successfully closed a public offering, raising approximately $2 million. The offering involved 3,333,338 shares of common stock, along with series A-1 and series A-2 warrants, each allowing the purchase of up to 3,333,338 additional shares at an exercise price of $0.60 per share. The Series A-1 Warrants are exercisable immediately and expire in five years, while the Series A-2 Warrants also become exercisable immediately but expire in eighteen months. The funds raised will be used for general working capital. H.C. Wainwright & Co. served as the exclusive placement agent for this offering.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.